Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Recombinant Protein / Other Proteins

Recombinant VACV A33R Protein, N-GST & C-His

Catalog #:   YVV14201 Specific References (13) DATASHEET
Applications: ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress
Expression system: E. coli
Accession: P68617
Protein length: Ser90-Asn185
Overview

Catalog No.

YVV14201

Expression system

E. coli

Species

Vaccinia virus (strain Western Reserve) (VACV) (Vaccinia virus (strain WR))

Protein length

Ser90-Asn185

Predicted molecular weight

39.10 kDa

Nature

Recombinant

Applications

ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress

Endotoxin level

Please contact with the lab for this information.

Purity

>90% as determined by SDS-PAGE.

Accession

P68617

Form

Lyophilized

Storage buffer

Lyophilized from a solution in PBS pH 7.4, 5% Trehalose, 2% Mannitol.

Reconstitution

Reconstitute in sterile water for a stock solution.

Shipping

In general, proteins are provided as lyophilized powder/frozen liquid. They are shipped out with dry ice/blue ice unless customers require otherwise.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.

Alternative Names

Protein OPG161, OPG161, VACWR156, A33R

Note

For research use only.

Data Image
  • SDS-PAGE
    SDS-PAGE for Recombinant Vaccinia virus (strain Western Reserve) (VACV) (Vaccinia virus (strain WR)) A33R protein
References

DNA vaccination with vaccinia virus L1R and A33R genes protects mice against a lethal poxvirus challenge., PMID:10639319

Four-gene-combination DNA vaccine protects mice against a lethal vaccinia virus challenge and elicits appropriate antibody responses in nonhuman primates., PMID:12620810

Differential efficacy of vaccinia virus envelope proteins administered by DNA immunisation in protection of BALB/c mice from a lethal intranasal poxvirus challenge., PMID:15308360

Subunit recombinant vaccine protects against monkeypox., PMID:16888017

Human T-cell responses to vaccinia virus envelope proteins., PMID:17005679

Heterogeneity in the A33 protein impacts the cross-protective efficacy of a candidate smallpox DNA vaccine., PMID:18482742

Targeting the vaccinia virus L1 protein to the cell surface enhances production of neutralizing antibodies., PMID:18485547

Modulation of the myxoma virus plaque phenotype by vaccinia virus protein F11., PMID:22514354

Epitope mapping by random peptide phage display reveals essential residues for vaccinia extracellular enveloped virion spread., PMID:23006741

Transport and stability of the vaccinia virus A34 protein is affected by the A33 protein., PMID:23255618

Active vaccination with vaccinia virus A33 protects mice against lethal vaccinia and ectromelia viruses but not against cowpoxvirus; elucidation of the specific adaptive immune response., PMID:23842430

Identification of 10 cowpox virus proteins that are necessary for induction of hemorrhagic lesions (red pocks) on chorioallantoic membranes., PMID:24850732

Levels of antibodies against the monkeypox virus compared by HIV status and historical smallpox vaccinations: a serological study., PMID:38767199

Datasheet
$ 313
Product specifications
100 μg 313 1 mg 1629

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

Recombinant VACV A33R Protein, N-GST & C-His [YVV14201]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2025 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only